Advertisement
UK markets close in 1 hour 40 minutes

  • FTSE 100

    8,054.99
    +14.61 (+0.18%)
     

  • FTSE 250

    19,579.18
    -140.19 (-0.71%)
     

  • AIM

    752.92
    -1.77 (-0.23%)
     

  • GBP/EUR

    1.1656
    +0.0012 (+0.10%)
     

  • GBP/USD

    1.2469
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    50,760.25
    -2,249.60 (-4.24%)
     

  • CMC Crypto 200

    1,364.08
    -18.49 (-1.34%)
     

  • S&P 500

    5,003.36
    -68.27 (-1.35%)
     

  • DOW

    37,887.39
    -573.53 (-1.49%)
     

  • CRUDE OIL

    82.63
    -0.18 (-0.22%)
     

  • GOLD FUTURES

    2,332.50
    -5.90 (-0.25%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,844.83
    -243.87 (-1.35%)
     

  • CAC 40

    7,970.15
    -121.71 (-1.50%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Merus to Participate in William Blair's Biotech Focus Conference 2021

Merus N.V.
·1-min read

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a panel discussion, Moving Beyond Monoclonals: The Potential of Multispecific Therapies, at William Blair's Biotech Focus Conference 2021 on Wednesday, July 14 at 11:20 a.m. ET.

The live webcast of the panel discussion will be available on the Investors page of the Company's website. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

CONTACT: Investor and Media Inquiries: Kathleen Farren Merus N.V. Communications Specialist 617-230-4165 k.farren@merus.nl